Arrevus, Inc.

Research Triangle Park, NC · Founded 2015 · Biotech · Acquired

Allo-aca, a second-generation leptin receptor (ObR) antagonist therapeutic for triple-negative breast cancer

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · arrevus.com

Sector: Biotech
Headquarters: Research Triangle Park, NC
Founded: 2015
Latest Form D: $150K, Sep 2019
Total capital: $5.7M

Federal grants: $4.2M; 11 awards · 2018–2023; Rank in peer group#215 of 514
Private capital raised: $1.4M; 3 Form D · last Sep 2019; 85 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 0; 10 pending

Capital timeline

Latest events

Apr 2023Federal grantHealth and Human S · Phase I · Leptin Receptor Agonist to Treat Sleep Disordered Breathing$320K
Aug 2022Federal grantHealth and Human S · Phase I · Leptin Receptor Agonist as a Novel Prevention of Opioid Induced Respiratory Depression$319K
Mar 2021Federal grantHealth and Human S · Phase I · Engineered adipokine receptor inhibitor for the treatment of triple negative breast cancer in obese patients$400K
May 2020Federal grantHealth and Human S · Phase I · Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating sepsis$300K
Feb 2020Federal grantHealth and Human S · Phase II · Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia$673K
Sep 2019Private capital raisedForm D · SEC · 3rd filing$150K
Mar 2019Federal grantHealth and Human S · Phase I · Use of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating antibiotic resistant pneumonia$295K
Aug 2018Private capital raisedForm D · SEC · 2nd filing$300K
May 2017Private capital raisedForm D · SEC · 1st filing$1.0M

Show 5 earlier federal awards

Feb 2019Federal grantHealth and Human S · Phase II · Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia$739K
Dec 2018Federal grantHealth and Human S · Phase I · Development of a predictive moderate throughput assay to screen novel Designer Proline-rich antimicrobial peptide Chaperone protein inhibitors (DPCs) against multi-drug resistant pathogen$299K
Jun 2018Federal grantHealth and Human S · Phase I · Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant urinary tract infections$295K
Feb 2018Federal grantHealth and Human S · Phase II · Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant bacteremia$297K
Jan 2018Federal grantHealth and Human S · Phase I · Development of a Designer Proline-rich antimicrobial peptide Chaperone protein inhibitor (DPC) for treating multi-drug resistant wound infections$300K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grants#215 · top 42%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Carl N. KrausResearcherExecutive Officer, Director, PromoterLinked by $999K in grants as PI
BARRY N GARFINKLEDirectorNamed in SEC Form D filings
DORIS N SNOWPromoterNamed in SEC Form D filings
Joe W. McMahonDirectorNamed in SEC Form D filings
Joseph W. St. GemeDirectorNamed in SEC Form D filings
ROBERT V HOUSEExecutive Officer, Director, PromoterNamed in SEC Form D filings

Show all 7 people

ROBERT N SCHOTZINGERDirectorNamed in SEC Form D filings

What it has protected

USPTO · 0 granted of 10

Aug 19, 2021PendingAntibacterial Peptide Monomers And Combinations For Co-therapyUSPTOApplication 17259301
Oct 15, 2020PendingAntibacterial Peptides And Combinations For Co-therapyUSPTOApplication 16954230
Jan 30, 2020PendingCompositions Comprising Fusidic Acid And Packages ThereforUSPTOApplication 16372687

Show all 10 patent records

Antibacterial Peptide Monomers And Combinations For Co-therapyAug 19, 2021 · Application 17259301Pending
Antibacterial Peptides And Combinations For Co-therapyOct 15, 2020 · Application 16954230Pending
Compositions Comprising Fusidic Acid And Packages ThereforJan 30, 2020 · Application 16372687Pending
Compositions And Methods For Treating Bone And Joint InfectionsDec 26, 2019 · Application 16278956Pending
Antibacterial Peptide Monomers And Combinations For Co-therapyApplication 62697019Pending
Antibacterial Peptides And Combinations For Co-therapyApplication 62697001Pending
Antibacterial Peptide and Antibiotic Combinations and Uses ThereofApplication 62599828Pending
Antibacterial Peptide Monomers And Combinations For Co-therapyApplication PCTUS2019041656Pending
Antibacterial Peptides And Combinations For Co-therapyApplication PCTUS2018066002Pending
Antibacterial Peptide Monomers And Combinations For Co-therapyApplication 62777897Pending

BEAT BIOTHERAPEUTICS CORPORATIONSimilar federal contract value in Biotech · null in contracts
OYAGEN, INC.Similar federal contract value in Biotech · null in contracts
PNA INNOVATIONS, INC.Similar federal contract value in Biotech · null in contracts
TOPAZ BIOSCIENCES, INC.Similar federal contract value in Biotech · null in contracts
ACCURIUS THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Goldilocks Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.